The purpose of this study to assess the pharmacokinetic profile in patients with active ulcerative colitis and compare it to the experience in healthy volunteers.

Inclusion Criteria:

• Active ulcerative colitis defined as a Mayo endoscopy score of ≥ 2 despite therapy.
• Male or female age 18 to 75
• May be receiving a therapeutic dose of an oral 5-amino salicylic acid compound or oral corticosteroid therapy

Exclusion Criteria:

• Current anti-tumor necrosis factor use
• Current immunosuppressant use (Note: this does not include corticosteroid use)
• Subjects with only distal active disease (i.e. proctitis)
• Clinically significant active infection
• Known bleeding disorder, a risk of bleeding or hypercoagulable disorders in which an anticoagulant is required
• History of malignancy within the last 5 years except non-melanoma skin cancer or cervical carcinoma in situ
• Clinically significant lab abnormalities (i.e. liver function abnormalities, renal insufficiency, abnormal absolute neutrophil count or hemoglobin)
• History of colon resection
• Any other investigational therapy or investigational biologics use within 8 weeks of investigational medicinal product administration